ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib is a tyrosine kinase inhibitor designed to inhibit BCR-ABL activity in chronic myelogenous leukemia (CML) that revolutionized the treatment of this hematopoietic malignancy in the early 2000s [46].